PB College Seminars Series
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
 QUICK SEARCH:   [advanced]


     


Psychiatric Bulletin (1998) 22: 548-551. doi: 10.1192/pb.22.9.548
© 1998 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Searle, G. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Searle, G. F.

Optimising neuroleptic treatment for psychotic illness

G. F. Searle, Consultant Psychiatrist

Dorset Healthcare NHS Trust, King's Park Unit, Gloucester Road, Boscombe, Bournemouth, BH7 6JE

The release of the antipsychotic agents risperidone, sertindole and olanzepine forces difficult choices upon clinicians. The new compounds are better tolerated than neuroleptics, expensive and their long-term side-effects unknown. These choices can be made easier by the dose and side-effect minimisation procedure set out below, which aims to produce the greatest benefit and least harm from conventional neuroleptics.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1998 The Royal College of Psychiatrists.